Internship
Customer Service Werkstudent
Pharma
Posted on 8/19/2026
Viatris
10,001+ employees
Global pharma selling generics and biosimilars
No salary listed
Bad Homburg, Germany
In Person
Bachelor's
 Customer Experience & Support (1) |
|---|
Get referred to Viatris
See people who can refer or advise you
- Currently pursuing business administration, economics, or a comparable degree program, with at least three semesters completed and regular enrollment maintained.
- Demonstrated customer and service orientation.
- Interest in sales-side and customer-related processes.
- Strong communication and teamwork skills.
- Structured and careful working style.
- Analytical thinking and problem-solving skills.
- Initiative and willingness to learn.
- Reliability and sense of responsibility.
- Basic knowledge of Microsoft Office 365.
- Very good German and good English language skills.
- Support the processing of customer orders from receipt through delivery, including invoicing and exposure to sales-side dunning processes.
- Help maintain and review customer master data, price lists, and commercial terms in the relevant systems.
- Learn the processes for returns and complaints and support their commercial processing.
- Communicate by telephone and in writing with customer groups including physicians, pharmacies, wholesalers, hospitals, and special customers.
- Collaborate with Key Account Management and the field sales team.
- Provide and prepare sales-relevant information for internal departments and external partners.
- Learn the defined order and fulfillment processes in Customer Service and support compliance with them.
- Support the identification and implementation of measures to improve efficiency in Customer Service Management.
- Actively participate in cross-functional project teams and support special orders and project-related tasks.
- Gain insight into reporting and monitoring of order and revenue development.
Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.
Company Size
10,001+
Company Stage
IPO
Headquarters
Canonsburg, Pennsylvania
Founded
1961
Get referred to Viatris
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $3.76 billion, and management raised full-year guidance.
- Gross leverage fell to 2.9x after repaying roughly $900 million debt.
- Fast-acting meloxicam has a December 27, 2026 FDA action date, supporting pipeline value.
What critics are saying
- Tyvarya rights sale to Harrow shrinks growth assets and signals portfolio pruning.
- Merck sitagliptin litigation still threatens U.S. generic launches through 2026 appeals.
- EpiPen settlements keep Mylan-era pricing conduct alive, risking future antitrust liabilities.
What makes Viatris unique
- Viatris spans branded, generic, and biosimilar medicines across 165 countries.
- Greater China delivered 21% Q2 2026 growth through established brands and e-commerce.
- FDA-approved Gwyn Lo and meloxicam add near-term proprietary launches.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 18%1 year growth
↑ 18%2 year growth
↑ 18%Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.
Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.
Viatris reported second-quarter 2026 revenues of $3.8 billion, representing 5% reported growth compared to the same period in 2025. The pharmaceutical company posted a US GAAP net loss of $119 million, primarily driven by a non-cash charge of $177.8 million related to the planned sale of Tyrvaya product rights. Adjusted EBITDA reached $1.2 billion, up 8% operationally year-over-year. The company returned approximately $550 million to shareholders, including roughly $270 million through share repurchases at a weighted average price of $16.42 per share. Viatris reduced its gross leverage ratio to 2.9x after repaying approximately $900 million in debt. The company raised its full-year 2026 financial guidance midpoints across all metrics. In July, Viatris received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch expected to launch later this year.
Viatris has received US FDA approval for Gwyn Lo, a low-dose estrogen contraceptive patch. The product adds a new branded option to the company's women's health portfolio. Gwyn Lo's approval comes as Viatris shares have shown strong momentum. The stock currently trades at $17.56, reflecting a 40.9% year-to-date return and 107.2% gain over the past year. The contraceptive patch may help diversify Viatris' revenue mix. Investors will be watching how quickly the product gains traction in prescribing patterns and market share. The company's shares trade close to the analyst price target of $17.94. However, Viatris carries a high forward price-to-earnings ratio of 57.84, and its 2.73% dividend yield is reportedly not well covered by earnings.
Viatris has secured a ¥40 billion (approximately $270 million) unsecured term loan facility with a syndicate of lenders led by Mizuho Bank. The three-year facility, which closed on 1 July 2026, will support general corporate purposes and refinance a prior loan of the same amount. The facility is priced at the TIBO Rate plus 1.10%, with pricing linked to Viatris' long-term credit ratings. It includes leverage ratio limits, standard covenants on indebtedness, dividends and mergers, plus default provisions allowing lenders to accelerate repayment. The loan is backed by guarantees from key Viatris subsidiaries and allows penalty-free prepayments, providing the pharmaceutical company with liquidity in the Japanese market whilst maintaining financial flexibility.